# Justification for the selection of a substance for CoRAP inclusion

Substance Name (Public Name): Oxybenzone

**Chemical Group:** 

**EC Number:** 205-031-5

**CAS Number:** 131-57-7

Submitted by: Denmark

**Published:** 26/03/2014

#### Note

This document has been prepared by the evaluating Member State given in the CoRAP update.

#### **Contents**

| 1 | IDE        | NTITY OF THE SUBSTANCE   | 3           |
|---|------------|--|-------------|
|   | 1.1        | Other identifiers of the substance   | 3           |
| 2 | 2.1<br>2.2 | SSIFICATION AND LABELLING Harmonised Classification in Annex VI of the CLP Self classification Proposal for Harmonised Classification in Annex VI of the CLP | 4<br>4<br>4 |
| 3 | INF        | ORMATION ON AGGREGATED TONNAGE AND USES  | 5           |
| 4 | 4.1        |  | 5<br>5<br>5 |
|   | 4.3        | Initial grounds for concern to be clarified under Substance Evaluation Other completed/ongoing regulatory processes that may affect suitability              | 6           |
|   |            | for substance evaluation  Preliminary indication of information that may need to be requested to clarify the concern   | 7           |
|   |            | Potential follow-up and link to risk management  | 7           |
|   |            |  |             |

#### 1 IDENTITY OF THE SUBSTANCE

#### 1.1 Other identifiers of the substance

**Table 1: Substance identity** 

| EC name:                                       | Oxybenzone  |  |  |
|--|---|--|--|
| IUPAC name:                                    | (2-hydroxy-4-methoxyphenyl) (phenyl) methanone  |  |  |
| Index number in Annex VI of the CLP Regulation | N.a.  |  |  |
| Molecular formula:                             | C14H12O3  |  |  |
| Molecular weight or molecular weight range:    | 228.2433  |  |  |
| Synonyms/Trade names:                          | Benzophenone-3  Methanone, (2-hydroxy-4- methoxyphenyl)phenyl-  2-hydroxy-4-methoxybenzophenone |  |  |

| Type of substance $oxtimes$ M | ono-constituent | ] Multi-constituent [ | UVCB |
|-------------------------------|-----------------|-----------------------|------|
|-------------------------------|-----------------|-----------------------|------|

#### Structural formula:

### 1.2 Similar substances/grouping possibilities

Table 2: Similar sbstances

| Name                          | CAS No    | EC No     | Comments                      |
|-------------------------------|-----------|-----------|-------------------------------|
| Benzophenone                  | 119-61-9  | 204-337-6 | Registered, SEV by DK in 2013 |
| Benzophenone-1                | 131-56-6  | 205-029-4 | Not registered                |
| Benzophenone-2                | 131-55-5  | 205-028-9 | Not registered                |
| Benzophenone-12 (octabenzone) | 1843-05-6 | 217-421-2 | Registered, SEV by IT in 2013 |

#### Structural formula:

Structural formula for Benzophenone, which constitute the backbone of all benzophenones:

#### 2 CLASSIFICATION AND LABELLING

#### 2.1 Harmonised Classification in Annex VI of the CLP

No entry.

#### 2.2 Self classification

• In the registration dossier:

Aquatic Acute 1 (H400)

Aquatic Chronic 1 (H410)

• The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

Skin Irrit 2 (H315)

Eye Irrit 2 (H319)

STOT SE 3 (H335)

STOT RE 2 (H373)

Aquatic Chronic 2 (H411)

Aquatic Chronic 4 (H413)

Not Classified

### 2.3 Proposal for Harmonised Classification in Annex VI of the CLP

No current proposal.

#### **3 INFORMATION ON AGGREGATED TONNAGE AND USES**

| From ECHA dissemination site   |                       |                   |                           |  |  |  |
|--|-----------------------|-------------------|---------------------------|--|--|--|
| ☐ 1 – 10 tpa   |                       | ı                 | ☐ 100 – 1000 tpa          |  |  |  |
| ☐ 1000 – 10,000 tpa  | ☐ 10,000 <b>–</b> 100 | 0,000 tpa         | ☐ 100,000 – 1,000,000 tpa |  |  |  |
| 1,000,000 - 10,000,00  | 0 tpa                 | - 100,000,000 tpa | ☐ > 100,000,000 tpa       |  |  |  |
| ☐ <1 > +   | tpa (e.g. 10+; 100+;  | 10,000+ tpa)      | ☐ Confidential            |  |  |  |
| Decreasing manufacture and import. The total use in the Nordic countries has decreased from approx. 800 tonnes per year in 1999 to approx. 75 tonnes per year in 2010 in less than 200 products registered (cf. SPIN database). Registered in 2013 for the 10-100 tpa range. |                       |                   |                           |  |  |  |
| ☐ Industrial use   | □ Professional use    |                   | ☐ Closed System           |  |  |  |
| According to publicly available information, oxybenzone is used as an UV absorber in cosmetics, personal care products and possibly also in paints, lacquers and varnishes (cf. SPIN database).  |                       |                   |                           |  |  |  |
| 4 JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE 4.1 Legal basis for the proposal  |                       |                   |                           |  |  |  |
| ☐ Article 44(2) (refined prioritisation criteria for substance evaluation)   |                       |                   |                           |  |  |  |
| Article 45(5) (Member State priority)  |                       |                   |                           |  |  |  |
| 4.2 Selection criteria met (why the substance qualifies for being in CoRAP)  |                       |                   |                           |  |  |  |
| ☐ Fulfils criteria as CMR/ Suspected CMR   |                       |                   |                           |  |  |  |
| ☐ Fulfils criteria as Sensitiser/ Suspected sensitiser   |                       |                   |                           |  |  |  |
| □ Fulfils criteria as potential endocrine disrupter  |                       |                   |                           |  |  |  |
| ☐ Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB  |                       |                   |                           |  |  |  |
| ☐ Fulfils criteria high (aggregated) tonnage (tpa > 1000)  |                       |                   |                           |  |  |  |
|  | re criteria           |                   |                           |  |  |  |
| □ Fulfils MS's (national) priorities   |                       |                   |                           |  |  |  |

#### 4.3 Initial grounds for concern to be clarified under Substance Evaluation

| Hazard based concerns  |                                     |                                 |  |  |  |  |
|--|-------------------------------------|---------------------------------|--|--|--|--|
| CMR<br>□C □M □R  | Suspected CMR <sup>1</sup> C M R    | ☐ Potential endocrine disruptor |  |  |  |  |
| Sensitiser   | ☐ Suspected Sensitiser <sup>1</sup> |                                 |  |  |  |  |
| ☐ PBT/vPvB   | ☐ Suspected PBT/vPvB <sup>1</sup>   | ☐ Other (please specify below)  |  |  |  |  |
| Exposure/risk based concer   | ns                                  |                                 |  |  |  |  |
| ☑ Wide dispersive use  | ☐ Consumer use                      |                                 |  |  |  |  |
|  | □ Exposure of workers               | ☐ Cumulative exposure           |  |  |  |  |
| ☐ High RCR   | ☐ High (aggregated) tonnage         | Other (please specify below)    |  |  |  |  |
| The registrant has concluded that none of the studies available to him demonstrate that oxybenzone is an endocrine disruptor.  However, the potential of the substance for being an endocrine disruptor was evaluated by the Danish Centre for Endocrine Disruptors in 2012 on contract for the Danish EPA. The study concluded that oxybenzone is a potential endocrine disruptor.  In addition, new research showing effects of oxybenzone on reproduction and endpoints |                                     |                                 |  |  |  |  |
| sensitive to endocrine disruption will be published later in 2014.   |                                     |                                 |  |  |  |  |
| Various available monitoring data show that oxybenzone can be found in human urine samples as well as in the aquatic environment.  |                                     |                                 |  |  |  |  |
| If the Substance Evaluation concludes that the substance is an endocrine disruptor, the exposure of and risks to consumers, incl. sensitive populations, workers as well as the environment needs to be further assessed.  |                                     |                                 |  |  |  |  |

<u>Suspected PBT</u>: Potentially Persistent, Bioaccumulative and Toxic

<sup>&</sup>lt;sup>1</sup> <u>CMR/Sensitiser</u>: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory) <u>Suspected CMR/Suspected sensitiser</u>: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-classification)

## 4.4 Other completed/ongoing regulatory processes that may affect suitability for substance evaluation

| Compliance check, Fi  | nal decision           | ☐ Dangerous substances Directive 67/548/EEC  |   |                                 |  |
|---|------------------------|--|---|---------------------------------|--|
| ☐ Testing proposal  |                        | ☐ Existing Substances Regulation 793/93/EEC  |   |                                 |  |
| ☐ Annex VI (CLP)  |                        | ☐ Pla  | ant Protection Prod                           | ucts Regulation 91/414/EEC      |  |
| ☐ Annex XV (SVHC)   |                        | ☐ Biocidal Products Directive 98/8/EEC; Biocidal Product Regulation (Regulation (EU) 528/2012) |   |                                 |  |
| ☐ Annex XIV (Authorisa  | ation)                 | ☐ Ot   | Other (provide further details below)         |                                 |  |
| ☐ Annex XVII (Restricti   | on)                    |  |   |                                 |  |
| Please provide further d  | letails when relevant. |  |   |                                 |  |
|   |                        |  |   |                                 |  |
|   |                        |  |   |                                 |  |
|   |                        |  |   |                                 |  |
|   |                        |  |   |                                 |  |
| 4.5 Prelimi   | inary indication       | of i   | nformation 1                                  | that may need to be             |  |
|   | ted to clarify th      |  |   | <b>,</b>                        |  |
| ☐ Information on toxicological properties   |                        |  | ☐ Information on physical chamical properties |                                 |  |
|   |                        | ☐ Information on physico-chemical properties   |   |                                 |  |
| ☐ Information on fate a   |                        | ☐ Information on exposure  |   |                                 |  |
| ☐ Information on ecoto  | xicological properties | ☐ Information on uses  |   |                                 |  |
| ☐ Information ED poter  |                        |  | ☐ Other (provide further details below)       |                                 |  |
| Please provide further details/explanation.   |                        |  |   |                                 |  |
|   |                        |  |   |                                 |  |
|   |                        |  |   |                                 |  |
|   |                        |  |   |                                 |  |
|   |                        |  |   |                                 |  |
| 4.6 Potential follow-up and link to risk management   |                        |  |   |                                 |  |
| ☐ Harmonised C&L ☐ Restriction  |                        |  |   | Other (provide further details) |  |
| If the suspicion of oxybenzone being an endocrine disruptor is confirmed, it might qualify for inclusion in the REACH candidate list for eventual inclusion in Annex XIV. |                        |  |   |                                 |  |
| If exposure data demonstrates levels exceeding safe levels, a restriction proposal might be required.   |                        |  |   |                                 |  |